Search

everythinglearnresearchcommunity

for

Search:↓

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Retinoids may help treat lupus nephritis and reduce steroid use.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

The LGBT-focused curriculum improved dermatology residents' confidence in treating LGBT patients.

RT1640 treatment reverses gray hair and promotes hair growth in mice.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Topical minoxidil, intralesional steroids, and cryotherapy significantly improve alopecia areata.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

The UD-PrOZA program successfully diagnosed 18% of adult patients with rare diseases, often using genetic testing.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Androgenetic alopecia trials in the U.S. lack racial and ethnic diversity, limiting their applicability.